These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results 2007-000854-30 A Randomized, Double-Blind, Placebo-Controlled Study of a Fixed Dose of Subcutaneous Methylnaltrexone in Adults With Advanced Illness and Opioid-Induced Constipation: Efficacy, Safety, and Additional ... 2012-07-27 due-trials
Reported results 2007-006107-20 Estudio de extensión abierto para evaluar la seguridad de una dosis fija de metilnaltrexona subcutánea en sujetos con enfermedad avanzada y estreñimiento inducido por opiáceos Open-Label Extension St... 2012-09-27 due-trials
Reported results 2013-002394-22 A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects with Irritable Bowel Syndrome with Diarrhoea (IBS-D) 2014-06-18 due-trials
Reported results Terminated 2014-001644-38 A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of ... 2018-11-26 due-trials
Reported results Terminated 2014-001645-24 A Double-Blind, Placebo-Controlled, Parallel-Group, Multicentre, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of ... 2018-12-31 due-trials
Ongoing 2020-005232-30 A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Parallel Group Study Evaluating the Efficacy and Safety of Amiselimod (MT-1303) in Subjects with Mild to Moderate Ulcerative Colitis (UC) not-yet-due

Related organisations

Over time organisations can merge, or split.

We think Salix Pharmaceuticals, Inc. is now effectively part of Bausch Health.